These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7813493)

  • 1. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia.
    Gaillat J; Bru JP; Sedallian A
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):639-44. PubMed ID: 7813493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.
    Balmes P; Clerc G; Dupont B; Labram C; Pariente R; Poirier R
    Eur J Clin Microbiol Infect Dis; 1991 May; 10(5):437-9. PubMed ID: 1651860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
    Lode H; Garau J; Grassi C; Hosie J; Huchon G; Legakis N; Segev S; Wijnands G
    Eur Respir J; 1995 Dec; 8(12):1999-2007. PubMed ID: 8666093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofloxacin in the treatment of lower respiratory tract infections: report of a prospective, comparative trial.
    Khajotia RR; Vetter N; Harazin H
    Clin Ther; 1991; 13(4):460-6. PubMed ID: 1933997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis.
    Rademaker CM; Sips AP; Beumer HM; Hoepelman IM; Overbeek BP; Möllers MJ; Rozenberg-Arska M; Verhoef J
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():75-81. PubMed ID: 2286595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe community-acquired pneumonia caused by atypical organisms.
    Monsieur I; Meysman M; Vincken W; Huyghens L; Lauwers S
    Acta Clin Belg; 1997; 52(2):112-5. PubMed ID: 9204587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
    Higuera F; Hidalgo H; Feris J; Giguere G; Collins JJ
    J Antimicrob Chemother; 1996 Mar; 37(3):555-64. PubMed ID: 9182112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etiology and treatment of community-acquired pneumonia in ambulatory children.
    Wubbel L; Muniz L; Ahmed A; Trujillo M; Carubelli C; McCoig C; Abramo T; Leinonen M; McCracken GH
    Pediatr Infect Dis J; 1999 Feb; 18(2):98-104. PubMed ID: 10048679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy with i.v. and oral ofloxacin in lower respiratory tract infections: a comparative study.
    Feist H
    Infection; 1991; 19 Suppl 7():S380-3. PubMed ID: 1804787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
    Oh HM; Ng AW; Lee SK
    Singapore Med J; 1996 Jun; 37(3):255-7. PubMed ID: 8942221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.